Genmab analyst raises price target to $40 amid revenue growth
GMAB
Statements (3)
- Bearish
Genmab's stock price is being adjusted downward by analysts due to concerns over its drug pipeline.
- Bullish
Genmab is likely to see further stock price appreciation due to increased drug royalties, which are expected to boost its revenue outlook.
- Bullish
Genmab delivered first-half revenue of $2.05 billion, a 25% increase from the prior period.